Written and maintained by CASRAI Editorial Board
Last updated
eCTD Module 3 (Quality) is where a submission lives or dies on detail. Unlike Module 2’s narrative overviews, Module 3 is a fixed, ICH M4Q-defined subsection tree, and reviewers read it section by section against that exact structure — not as free-form prose. This guide maps every subsection of 3.2.S (Drug Substance) and 3.2.P (Drug Product), what belongs in each one, and the granularity FDA and EMA reviewers expect at each level, so quality teams can build (or audit) a Module 3 quality section against the actual ICH M4Q table of contents rather than a rough approximation of it. For the five-module eCTD hierarchy this sits inside, see CASRAI’s eCTD Structure for Clinical Submissions guide — this page goes one level deeper, into Module 3’s internal subsection structure specifically.
Why Module 3’s structure is not optional
Module 3 implements ICH M4Q, the quality module of the Common Technical Document. Its subsection numbering — 3.2.S.1 through 3.2.S.7 for drug substance, 3.2.P.1 through 3.2.P.8 for drug product — is not a suggested outline; it is the filing structure FDA’s and EMA’s reviewers use to navigate directly to a specific claim. A batch analysis result filed under 3.2.S.2 (Manufacture) instead of 3.2.S.4.4 (Batch Analyses) is not just untidy — it is effectively invisible to a reviewer working section-by-section against the ICH table of contents, and can trigger an information request that a correctly-placed document would have avoided.
Each subsection also carries its own reference guidelines — the specific ICH quality guideline (Q2, Q3, Q5, Q6, and related) that governs what “complete” looks like for that subsection. Getting the placement right and meeting the referenced guideline’s expectations are two separate checks; this page covers both.
3.2.S Drug Substance, section by section
3.2.S is filed once per drug substance (repeated in full for each distinct substance in a combination product). Every subsection is captioned (name, manufacturer) in the ICH template — reviewers expect the substance name and manufacturer identified in the section header itself, not just in Module 1 administrative content.
| Subsection | What it covers | Referenced ICH guidelines |
|---|---|---|
| 3.2.S.1 General Information | Nomenclature (3.2.S.1.1: INN, compendial name, CAS number), structure (3.2.S.1.2: structural formula, molecular formula, stereochemistry), general properties (3.2.S.1.3: physicochemical and biological properties) | Q6A, Q6B |
| 3.2.S.2 Manufacture | Manufacturer identity and site (3.2.S.2.1), process description and controls (3.2.S.2.2), control of materials (3.2.S.2.3), control of critical steps and intermediates (3.2.S.2.4), process validation (3.2.S.2.5), manufacturing process development history (3.2.S.2.6) | Q6A, Q6B; viral safety detail cross-references 3.2.A.2 |
| 3.2.S.3 Characterisation | Structure elucidation (3.2.S.3.1), impurities (3.2.S.3.2) | Q3A, Q3C, Q5C, Q6A, Q6B |
| 3.2.S.4 Control of Drug Substance | Specification (3.2.S.4.1), analytical procedures (3.2.S.4.2), validation of those procedures (3.2.S.4.3), batch analyses (3.2.S.4.4), justification of specification (3.2.S.4.5) | Q2A, Q2B, Q3A, Q3C, Q6A, Q6B |
| 3.2.S.5 Reference Standards or Materials | No further subsections — a single, complete narrative | — |
| 3.2.S.6 Container Closure System | No further subsections | — |
| 3.2.S.7 Stability | Stability summary and conclusions (3.2.S.7.1), post-approval stability protocol and commitment (3.2.S.7.2), stability data (3.2.S.7.3) | Q1A, Q1B, Q5C |
3.2.P Drug Product, section by section
3.2.P mirrors 3.2.S structurally but runs one subsection longer, because a finished product carries composition, excipient control, and pharmaceutical-development narrative that a drug substance filing doesn’t. Every subsection is captioned (name, dosage form).
| Subsection | What it covers | Referenced ICH guidelines |
|---|---|---|
| 3.2.P.1 Description and Composition | Dosage form description and full quantitative composition — no further subsections | — |
| 3.2.P.2 Pharmaceutical Development | Components (3.2.P.2.1: drug substance and excipient compatibility), the drug product itself (3.2.P.2.2: formulation development, overages, physicochemical/biological properties), manufacturing process development (3.2.P.2.3), container closure system (3.2.P.2.4), microbiological attributes (3.2.P.2.5), compatibility with diluents/devices (3.2.P.2.6) | Referenced throughout by the more specific control sections below |
| 3.2.P.3 Manufacture | Manufacturer(s) (3.2.P.3.1), batch formula (3.2.P.3.2), process description and controls (3.2.P.3.3), controls of critical steps and intermediates (3.2.P.3.4), process validation (3.2.P.3.5) | Q6B; viral safety cross-references 3.2.A.2 |
| 3.2.P.4 Control of Excipients | Specifications (3.2.P.4.1), analytical procedures (3.2.P.4.2), validation (3.2.P.4.3), justification (3.2.P.4.4), excipients of human/animal origin (3.2.P.4.5), novel excipients (3.2.P.4.6) | Q2A, Q5A, Q5D, Q6A, Q6B |
| 3.2.P.5 Control of Drug Product | Specifications (3.2.P.5.1), analytical procedures (3.2.P.5.2), validation (3.2.P.5.3), batch analyses (3.2.P.5.4), characterisation of impurities (3.2.P.5.5), justification (3.2.P.5.6) | Q2A, Q3B, Q6A, Q6B |
| 3.2.P.6 Reference Standards or Materials | No further subsections | — |
| 3.2.P.7 Container Closure System | No further subsections | — |
| 3.2.P.8 Stability | Stability summary and conclusion (3.2.P.8.1), post-approval stability protocol and commitment (3.2.P.8.2), stability data (3.2.P.8.3) | Q1A, Q1B, Q2A, Q2B, Q5C |
3.2.A Appendices and 3.2.R Regional Information: the parts sponsors misfile most
Two sections sit outside the S/P mirror and exist specifically to hold content that would otherwise get duplicated or misplaced inside the substance/product sections:
- 3.2.A.1 Facilities and Equipment — manufacturing-facility detail, most relevant for biotech/novel-modality products.
- 3.2.A.2 Adventitious Agents Safety Evaluation — this is where viral clearance and adventitious-agent safety data actually belongs. 3.2.S.2.3, 3.2.S.2.5, 3.2.P.3.5, and 3.2.P.4.5 each explicitly cross-reference back to 3.2.A.2 rather than duplicating the underlying safety-evaluation data in place — a tabulated summary of viral-clearance reduction factors from 3.2.A.2 is what gets referenced from the relevant S/P subsections, not restated in full.
- 3.2.A.3 Excipients — full manufacture, characterisation, and control detail for a genuinely novel excipient (one used for the first time in any drug product, or by a new route of administration), filed in the same format as a drug substance. 3.2.P.4.6 (Novel Excipients) points here rather than restating it.
- 3.2.R Regional Information — content that is real and expected but not common to all ICH regions, so ICH deliberately left its section titles as examples rather than a fixed list. What actually goes here is set by the receiving authority’s own regional guidance (FDA’s Data Standards Catalog and technical conformance guides for a US filing; EMA’s eCTD regional guidance for an EU filing) — don’t assume a 3.2.R structure that worked for one authority transfers unchanged to another, the same region-specific caveat that applies to Module 1.
The granularity reviewers actually expect
The ICH M4Q template captions almost every subsection down to the leaf level with a placeholder like (name, manufacturer) or (name, dosage form) — a structural signal, not decoration, that each of these sections should be complete and identifiable on its own, because a reviewer or a later lifecycle amendment may reference it individually rather than the section as a whole. Three granularity patterns matter in practice:
- Leaf-level completeness, not summary-then-detail. A subsection like 3.2.S.4.1 (Specification) is expected to state the actual specification — not summarize it with “see analytical report attached.” The narrative and the supporting data belong together at the subsection the ICH table of contents assigns them to.
- Cross-references replace duplication, they don’t replace placement. Where ICH explicitly designs a cross-reference (S.2.3/S.2.5/P.3.5/P.4.5 pointing to 3.2.A.2; P.4.6 pointing to 3.2.A.3; P.5.5 for impurity characterisation feeding P.8.3 stability data), the underlying data still needs to exist at its designated home section in full — the cross-reference tells a reviewer where to look, it isn’t a substitute for having filed the content there.
- Subsection-level granularity is what makes lifecycle amendments manageable. Because the eCTD backbone assigns a lifecycle operation (new/append/replace/delete) per leaf document, filing content at the correct, granular subsection the first time is what lets a later amendment replace, say, just 3.2.S.4.4 (Batch Analyses) with updated data — without touching or resubmitting the rest of 3.2.S.4. A quality section that lumps several subsections into one oversized document forces a full-document replace for even a minor update, which is exactly the kind of structural choice that makes later changes painful. See CASRAI’s eCTD structure guide for how the XML backbone’s lifecycle operations work at the sequence level.
Module 3 quality vs. the Module 2.3 Quality Overall Summary
Module 2.3 (Quality Overall Summary, part of the Module 2 CTD summaries) is not a shorter version of Module 3 — it is a separate, summary-level document that follows the same S/P/A/R heading structure as Module 3 but at a higher level of abstraction, written to let a reviewer orient before descending into Module 3’s full data. Content belongs in Module 3 if it’s the underlying data, method, or specification itself; it belongs in the Module 2.3 summary if it’s a synthesis of what Module 3 already contains. Duplicating full Module 3 detail into 2.3, or leaving 2.3 as a bare cross-reference with no actual summary, are both common review-cycle triggers.
Frequently asked questions
What is 3.2.S in eCTD Module 3?
3.2.S is the Drug Substance section of Module 3 (Quality), covering the active pharmaceutical ingredient: general information, manufacture, characterisation, control, reference standards, container closure, and stability, in seven numbered subsections (3.2.S.1 through 3.2.S.7) per ICH M4Q.
What is 3.2.P in eCTD Module 3?
3.2.P is the Drug Product section of Module 3, covering the finished dosage form: description and composition, pharmaceutical development, manufacture, control of excipients, control of the drug product, reference standards, container closure, and stability — eight numbered subsections (3.2.P.1 through 3.2.P.8) per ICH M4Q.
Where does viral safety data go in Module 3?
In 3.2.A.2 (Adventitious Agents Safety Evaluation), not inside the 3.2.S or 3.2.P sections that reference it. Subsections such as 3.2.S.2.3, 3.2.S.2.5, 3.2.P.3.5, and 3.2.P.4.5 cross-reference 3.2.A.2 rather than restating the underlying safety-evaluation data in place.
What’s the difference between 3.2.A and 3.2.R?
3.2.A (Appendices) holds specific, ICH-defined content — facilities and equipment, adventitious agents safety evaluation, and novel excipient detail — that applies the same way across ICH regions. 3.2.R (Regional Information) holds content that is expected but region-specific; ICH deliberately leaves its exact section titles as examples, and what actually goes there is set by each receiving authority’s own regional guidance.
Is Module 3 the same for FDA and EMA submissions?
The 3.2.S and 3.2.P subsection structure is ICH-harmonized and used the same way for FDA, EMA, and other ICH regulatory authorities. 3.2.R (Regional Information) and the region-specific administrative content in Module 1 are the parts that differ and must be rebuilt separately for each authority.
Related CASRAI resources
See the eCTD Structure for Clinical Submissions guide for the full five-module hierarchy and the XML backbone/lifecycle-operation mechanics this page’s granularity section builds on, the eCTD and ICH M4 (CTD) dictionary terms for the underlying standards, and the Chemistry, Manufacturing, and Controls (CMC) term for the discipline Module 3 quality data comes from. For adjacent GxP and quality-systems content, see Good Manufacturing Practice (GMP): A Guide for Research Institutions and Data Integrity in Pharmaceutical Manufacturing. For the broader vertical, see the Laboratory Compliance & Quality pillar.
